Clinical Platform Leverage ExpreS2ion’s proprietary ExpreS2 expression system and cVLP platform to position as a scalable solution for fast-tracking vaccine and immunotherapy candidate production, appealing to partners seeking efficient GMP-ready protein production and stable, cost-effective VLP-based vaccines.

Pipeline Synergy Target collaborations around the ES2B-C001 breast cancer vaccine and Nipah vaccine prospects, highlighting modular plug-and-play cVLP capabilities and potential applicability to other viral and cancer vaccines to attract co-development or licensing deals.

Strategic Partnerships Capitalise on the 34%-owned AdaptVac collaboration and ongoing academic sponsor relationships for joint development opportunities, offering other biotech firms access to established VLP platforms, glycosylation variants, and proven protein/VLP production track record.

Geographic Footprint Position as a Nordic-based clinical-stage partner with global outreach through investor and industry events in Europe and Asia, leveraging Nasdaq First North Growth Market visibility to attract international partnerships and potential co-financing arrangements.

Market Readiness Emphasise GLP safety study progress and preclinical/clinical milestones to de-risk collaborations, offering contract development and manufacturing organization (CDMO) style services around protein production, VLP manufacturing, and translational support for vaccine programs.